The global multiple sclerosis therapeutics market was valued at US$ 19,653.7 million in 2016 and is further estimated to exhibit a decent CAGR of 2.5% over the forecast period (2017-2025).
The proposed launch of potential pipeline candidates, the presence of potential regional markets, and increasing government initiatives aimed at eliminating the disease in Asia Pacific, Latin America, the Middle East, and Africa, are some of the indispensable factors fostering the growth of the global multiple sclerosis therapeutics market.

Key Takeaways:
• Based on drug class, the corticosteroids segment leads the global market owing to the multiple advantages offered by these drugs, such as lower risk of side effects and higher number of drug candidates in the pipeline.
• On the basis of route of administration, the injectables segment dominates the global market, owing to the higher recommendations of the doctors as the drugs administered by this route have instant mode of action.

Browse Research Reports: https://www.coherentmarketinsights.com/market-insight/multiple-sclerosis-therapeutics-market-1310

Leading Players:
The major players operating in the global multiple sclerosis therapeutics market include Novartis AG, Teva Pharmaceuticals Industries Ltd. Sanofi Genzyme, Bayer AG, Pfizer, Inc., Biogen Idec, Merck & Co. Inc. and AbbVie, Inc.
Market Scope:
The key market players have been concentrating on drug discovery to strengthen their drug development processes and accelerate the delivery of new treatments to patients living with the condition, thus augmenting the multiple sclerosis therapeutics market in the foreseeable period. For instance, in 2017, TG Therapeutics, Inc., signed an agreement with the U.S. Food and Drug Administration (FDA) regarding the Special Protocol Assessment (SPA) of the phase 3 clinical trials for TG-1101, which is an anti-D20 monoclonal antibody intended = for the treatment of relapsing forms of multiple sclerosis. Furthermore, in 2017, Antisense Therapeutics announced the proceeding of its Phase 2b clinical trials as the U.S. FDA lifted the clinical hold for the drug candidate ATL1102.

To learn more about this report, request a sample copy*
* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy of this report: https://www.coherentmarketinsights.com/insight/request-sample/1310

The introduction of new, efficient and promising B-cell targeted therapies acts as a vital growth factor for the global multiple sclerosis therapeutics market. For instance, in 2017, the FDA approved Genentech’s Ocrevus (ocrelizumab) a humanized monoclonal antibody targeting B-cells with CD20 molecule.
In 2011, Sanofi SA acquired Genzyme for a sum of US$ 20.1 billion and further acquired the rights for Genzyme’s injectable drug Lemtrada which was FDA approved in 2014 for the treatment of relapsing remitting multiple sclerosis. In 2015, Actelion Ltd., initiated Phase III development with ponesimod, which is a selective S1P1 receptor modulators in patients suffering from relapsing multiple sclerosis. Actelion Ltd. was acquired by Johnson & Johnson in 2017, gaining access to the pipeline drug candidate, thus expanding product portfolio.
In 2017, Sanofi SA joined forces with Principia Biopharma, Inc., for the development of potential multiple sclerosis oral drug candidate PRN2246, which is a tyrosine kinase inhibitor currently undergoing clinical development. In 2014, Accelerated Cure Project for MS, Feinstein Kean Healthcare and Complex Adaptive Systems at Arizona State University came together to create iConquerMS.

Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/1310

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
[email protected]
U.S. Office:
Name: Mr. Shah
Coherent Market Insights 1001 4th Ave,
# 3200 Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737